FEMSelect Poised for Market Leadership with Strategic Advancements in Women's Health
Summary
FEMSelect Announces Close of Oversubscribed Series B Equity Financing to Drive Commercial Growth, Leadership Transformation, and Global ExpansionNEW YORK, May 13, 2025 /PRNewswire/ -- FEMSelect, a privately held women-led company revolutionizing pelvic organ prolapse (POP) treatment with its groundbreaking EnPlace\xae technology, today announced significant advancements as part of its strategic roadmap to become a global leader in womens health. "With participation from long-time and new investors, this influx of capital marks a major leap forward in our mission to redefine care for millions of underserved women worldwide," said Renee Selman, Executive Chairwoman of the Board. "With a strengthened leadership team, expanded financial firepower, and a powerful product pipeline, FEMSelect is poised to accelerate growth and lead the way in transformative womens health solutions. This strategic move positions FEMSelect to capitalize on emerging opportunities and strengthen its presence in key regions worldwide.FEMSelect is also pleased to report that Rakesh Tailor, CEO of Contura International, was appointed to the Board of Directors. Given his experience in womens health and having led the development Bulkamid and its sale to Axonics in 2021, his strategic insight will help propel the companys presence in the U.S. and international markets.Strategic Relocation to the U.S.As part of its growth strategy, FEMSelect is relocating its headquarters from Israel to the United States, aligning the company closer to its largest market and expanding opportunities for strategic partnerships.FEMSelect is at the forefront of womens health, delivering innovative solutions for pelvic organ prolapse with its EnPlace technology.